AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: PlaceboDrug: Aclidinium Bromide
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 181
- Registration Number
- NCT00500318
- Locations
- 🇺🇸
Forest Investigative Site 0974, Pensacola, Florida, United States
🇺🇸Forest Investigative Site 0988, Sacramento, California, United States
🇺🇸Forest Investigative Site 0887, Los Angeles, California, United States
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 163
- Registration Number
- NCT00500370
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
AZD1152 in Patients With Advanced Solid Malignancies-Study 1
Phase 1
Terminated
- Conditions
- Solid Tumors
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2009-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00497731
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
Phase 1
Terminated
- Conditions
- Solid Tumours
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2009-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00497679
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Myeloid Leukemia
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00497991
- Locations
- 🇳🇱
Research Site, Rotterdam, Netherlands
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT00496470
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Phase I Study in Patients With Solid Tumours
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2010-09-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 148
- Registration Number
- NCT00496028
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00494234
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
Phase 1
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 172
- Registration Number
- NCT00494221
- Locations
- 🇯🇵
Research Site, Saitama, Japan
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Neoplasm
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT00494442
- Locations
- 🇸🇪
Research Site, Lund, Sweden
© Copyright 2025. All Rights Reserved by MedPath